R E V I E W A R T I C L EAmyloid-fibril formation Proposed mechanisms and relevance to conformational disease Eva Zˇerovnik Department of Biochemistry and Molecular Biology, Jozˇef Stefa
Trang 1R E V I E W A R T I C L E
Amyloid-fibril formation
Proposed mechanisms and relevance to conformational disease
Eva Zˇerovnik
Department of Biochemistry and Molecular Biology, Jozˇef Stefan Institute, Ljubljana, Slovenia
The phenomenon of the transformation of proteins into
amyloid-fibrils is of interest, firstly, because it is closely
connected to the so-called conformational diseases, many of
which are hitherto incurable, and secondly, because it
remains to be explained in physical terms (energetically and
structurally) The process leads to fibrous aggregates in the
form of extracellular amyloid plaques, neuro-fibrillary
tangles and other intracytoplasmic or intranuclear
inclu-sions In this review, basic principles common to the field of
amyloid fibril formation and conformational disease are
underlined Existing models for the mechanism need to be tested by experiment The kinetic and energetic bases of the process are reviewed The main controversial issue remains the coexistence of more than one protein conformation The possible role of oligomeric intermediates, and of domain-swapping is also discussed Mechanisms for cellular defence and novel therapies are considered
Keywords: amyloid fibrils; conformational disease; domain swapping; kinetics; mechanism of fibrillogenesis
Protein folding is important for cellular events ranging from
transport, accepting and transmitting signals, regulation at
the gene and RNA levels, cell adhesion, changes in
cytoskeleton, metabolic reactions involving various
enzymes, etc An active protein conformation is needed
for successful cell functioning, and therefore important in
maintaining health Several types of disease have been
found where protein misfolding and conformational change
are the main causes of the appearance and progression of
disease [1]
A list of conformational diseases, together with their
associated protein component(s), is shown in Table 1 [2] In
some cases, more than one protein is involved with a
disorder, coexisting in a plaque or making its formation
easier Often, proteolytically degraded fragments are more
prone to forming fibrils, e.g amyloid precursor protein
(APP) where a, b and c secretases [3,4] are responsible for
the initial processing, huntingtin and possibly also
a-synuc-lein [5]
In Alzheimer’s disease, which represents a major problem
in the Western world’s ageing population, the main protein
component is APP, a transmembrane protein of
approxi-mately 700 amino-acid residues [3,4,6,7] In its normal
processing Ab (1–40) peptide is produced which circulates
extracellularly and usually does not deposit as plaques It
has been proposed that the peptide may exert an
antioxi-dative function [8] In sporadic cases, especially when
allele 4 of apolipoprotein E is present, the peptide starts to
form amyloid plaques In the familial, more severe early-onset cases, prevalence of the hydrophobic Ab (1–42) peptide leads to extensive amyloid plaque formation This has been linked to mutations in the APP and presenilins 1 and 2 [7], which all increase the production of the more fibrillogenic Ab (1–42) peptide Fibrillary tangles of another protein, sau, are observed in the cell sau is a microtubule-associated protein involved in stabilizing axonal microtubules Other functions include a role in signal transduction, and anchoring various kinases and phospha-tases [9] Importantly, an anti-amyloidogenic protein, gelsolin, has been found in plasma and central system fluid (CSF) This secretory protein is able, by making complexes with Ab, to inhibit fibril formation and even to break down already formed fibrils [10] Recently, it has been found that the endopeptidase neprilysin degrades Ab peptide In neprilysin gene-disrupted mice Ab was found to accumu-late, with the highest levels in the hippocampus [11]
In Parkinson’s disease, which is the second most common neurodegenerative disease, several proteins are implicated, a-synuclein, synphilin (an a-synuclein inteacting protein) and parkin [12] a-Synuclein is a small (140 amino acid) acidic protein It is a naturally unfolded, intracellular and presynaptic polypeptide that becomes partly helical on binding to synaptic vesicles [13] Its function may be, among others, regulation of synaptic vesicles and neurotransmitter release [13] It is interesting that a-synuclein is a target of serine/threonine [14] as well as tyrosine [15,16] kinases A hallmark of Parkinson’s disease is the presence of Lewy bodies, which are found in sporadic cases of Parkinson’s disease, in dementia with Lewy bodies and in the Lewy body variant of Alzheimer’s disease [17] a-Synuclein is the main component of the Lewy bodies [18] Both a-synuclein and synphilin are required for formation of the Lewy bodies where ubiquitination of synphilin probably takes place [12,17] Parkin is a 465-amino-acid ubiquitin-protein ligase [17,19] Mutations in parkin and a-synuclein, in familial cases of Parkinson’s disease, prevent proper ubiquitination,
Correspondence to E Zˇerovnik, Department of Biochemistry and
Molecular Biology, Jozˇef Stefan Institute, Jamova 39, 1000 Ljubljana,
Slovenia E-mail: eva.zerovnik@ijs.si
Abbreviations: APP, amyloid precursor protein; Ab, amyloid b
pep-tide; CSF, central system fluid; AFM, atomic force microscopy; EM,
electron microscopy.
(Received 28 January 2002, revised 1 May 2002,
accepted 27 May 2002)
Trang 2so that proteins are not sequestered in the inclusion bodies,
leading to greater toxicity [12]
Even the prion diseases, a range of transmissible
spongi-form encephalophaties (kuru, Creuzfeldt–Jacob disease and
fatal familial insomnia in humans, bovine spongiform
encelopathy in cattle, scrapie in sheep, and chronic wasting
disease in deer) have many features in common with
amyloidoses and most likely are conformational [20] No
other agent accompanying the prion protein like virus
(DNA–protein) or bare DNA has convincingly been shown
in the infected tissue [21] The transmission could be
explained solely by inducing a wrong, irreversible
conform-ational change, resistant to proteolysis, leading to
accumu-lation of harmful protein aggregates This hypothesis has
recently been confirmed by inducing disease in transgenic
mice inoculated by b rich conformation of mutant P101L
(89–143) peptide of the human prion protein [21], in contrast
to the ones inoculated by non-b-form of the peptide
The term amyloid was introduced in 1854 by the
German physician R Virchow, who named it in the belief
that the iodine-staining component was starch-like [22,23]
The first criterion for detecting amyloid ex vivo was
birefringence of the histological dye Congo Red, observed
under polarized light As the second criterion, electron
microscopy showed that all amyloid deposits exhibited a
similar fibrillar, submicroscopic structure, bundles of
straight, rigid fibrils ranging in width from 60 to 130 A˚
and in length from 1000 to 16000 A˚ [23] In addition to the
fibrillar component of amyloid, nonfibrillar components
were always found, including serum amyloid protein,
heparan sulfate proteoglycans and apolipoprotein E [23]
The importance of the nonprotein and nonfibrillar
compo-nents of amyloid as observed in vivo remains to be
determined In vitro studies of the disease related proteins,
as well as other amyloidogenic proteins, have been
concerned mostly with the morphology and kinetics of
fibrillogenesis
It was concluded by Soto [20] that the pathogenesis of all
the conformational diseases, including prion disease,
involves conformational changes leading to aberrantly
folded proteins, rich in b secondary structure that have a high tendency to form aggregates and are quite resistant to proteolysis [20,24] The field is characterized by several scientific findings that challenge some of the commonly held dogmas in biology [24] These findings are that a protein can exist in more than one conformation with distinct biological properties, and that biological function is mediated through changes in protein conformation Some of the basic principles underlying protein fibril formation are described
in the following sections
F I B R I L F O R M A T I O N , A G E N E R A L
P R O P E R T Y O F P R O T E I N S A N D
P O L Y P E P T I D E S ?
Several authors have found that proteins that have not been associated with any disease can form amyloid-like fibrils [25–31] Especially surprising was the finding that even
a helical proteins, such as myoglobin [32] or apo-cyto-chrome c [33] can form fibrils under certain conditions These observations led Dobson and coauthors to propose that amyloid-fibril formation is a generic property of proteins [27,32,34] A common observation is that fibrilli-zation starts from an intermediate state, either partially unfolded or partially folded, molten globule or native-like intermediate [35] In the case of globular proteins such as phosphoglycerate kinase [25], cystatin C [36], acylphospha-tase [29] and transthyretin [37], partial unfolding needs to occur to enable fibril formation and, in the case of unfolded polypeptides such as a-synuclein [38,39] and islet amyloid polypeptide, these must partially fold The parts with the
a helical structure must undergo an a to b transition and the
b strands then associate into a regular fibrillar structure An
a to b transformation is well characterized with peptides, like poly(L-lysine) It has more recently been observed with proteins which are initially unfolded or predominantly
b sheet [40–42] and which fold through an a helical intermediate [43–46]
In vitro, variation of solvent conditions by changing pH
or adding organic solvents [47] can lead to partial unfolding
Table 1 Protein fibrillar inclusions in neurodegenerative and other types of diseases Data from [2,100] TSE, transmissible spongiform encephalopathies.
Neurodegenerative
Alzheimer’s sau, A42b peptide Neurofibrillary tangles
Progressive supranuclear palsy (PSP) sau, heat shock proteins Neurofibrillary tangles
Dementia with Lewy bodies a-Synuclein Lewy bodies/cytoplasmic Parkinson’s a-Synuclein, crystallins Neurofilaments/cytoplasmic Huntington’s Expanded Glu repeats of Intranuclear inclusion
huntingtin Spinocerebellar ataxias (SCA) Expanded Glu repeats of Intranuclear inclusion
ataxins 1,3,7 TSE Prion protein, cathepsin B Endosome-like organelles System amyloidosis
Haemodialysis related A b-2 Microglobulin
Reactive amyloidosis Amyloid A
Cystic fibrosis CFTR protein
Trang 3and subsequent protein fibril formation [29,48] With
unfolded polypeptides, partial folding can be obtained by
lowering pH or by heating [39] In vivo, partial unfolding
may happen as a consequence of lowered protein stability
due to mutation, local change in pH at membranes,
oxidative and heat stress, whereas partial folding may
happen on exposure to environmental hydrophobic
sub-stances, such as pesticides [39]
A M Y L O I D O G E N I C C O N F O R M A T I O N
A N D C O M M O N S T R U C T U R A L
T R A I T S O F T H E F I B R I L S
Amyloid fibrils cannnot be observed in solution whereas the
preamyloidogenic conformation can be trapped in
crystal-line or soluble form NMR data exist on the native-like acid
intermediate of transthyretin [49] where the authors have
used hydrogen exchange in conjunction with NMR to trace
structural features of the preamyloidogenic conformation
Similarly, by using hydrogen exchange in the native state,
the labile parts of the prion peptide have been determined
[50] NMR has been used in combination with electrospray
ionization mass spectrometry (ESI MS) to enable the
population of the intermediate to be seen [51] Recently,
crystal structures of the domain-swapped dimers of human
cystatin C [52] and prion peptide [53] have been determined
A solution structure of human stefin A (type I cystatin)
dimer is also available [54] and confirms the main features
observed in crystal structure of cystatin C
Ordered fibrillar aggregates and the amyloid-fibrils
themselves can be studied at lower resolution by
trans-mission electron microscopy, atomic force microscopy
(AFM) [55,56], cryo-electron mycroscopy [57], X-ray
diffraction [58] and solid state NMR [59] The fibrils
appear long, of indefinite length, unbranched, with repeats
that reflect the twisting of the component filaments
around one another [60–62] Common features of the
fibrils are [58], b strands (separated by 4.7 A˚) running
perpendicular to the long axis of the fibrils and b sheets
extending parallel to this axis The b strands form a
b helical twist with the usual repeat at every 115 or 250 A˚
[56,58] There are two main types of the fibrils, type 2
fibrils are built from two intertwined filaments, with a
diameter from 80 to 130 A˚ Type 1 fibrils are thinner and
are formed from one filament only There are other types
of fibrils [62]; for example, a fibril and untwisted filaments
of human stefin B [31] (type I cystatin) are illustrated in
Fig 1
E N E R G E T I C A N D K I N E T I C B A S I S
O F F I B R I L L O G E N E S I S
The molecular and energetic basis of protein misfolding and
amyloid fibrillogenesis is still largely unknown [20,63] In the
conclusion to their review, Rochet & Lansbury [35] propose
that future research should be directed towards
understand-ing the mechanism of amyloid-fibril formation, includunderstand-ing
environmental factors, such as temperature, ionic strength,
pH and oxidation potential Proteins have been treated as
an ensemble of rapidly interconverting conformational
substates In contrast, recent studies have shown that
interconversion between different conformations may be
slow (taking hours to days) For certain proteins the folding
appears to be determined by kinetic rather than thermody-namic factors [64] The free-energy barriers can be quite high [64–66], leading to persistence of parallel states, which possibly exhibit different biological functions The forces involved are nonspecific, e.g hydrophobic and repulsive electrostatic, and specific, e.g hydrogen bonding and salt-bridges As cooling causes reversible disaggregation of Ab fibrils, a significant contribution to stability must come from entropy-driven hydrophobic interactions This led to trials
of various hydrophobic compounds that should be effective
in destabilizing and disaggregating amyloid fibrils
Fig 1 Transmission electron micrographs (A) Amyloid fibrils of human recombinant stefin B (cystatin B) prepared in vitro at pH 4.8, showing a b helical repeat (B) Porous fibrillar aggregate and fine structure of a fibril (made from four filaments) resulting from the addition of trifluoroethanol.
Trang 4Despite enormous efforts, description of the process of
fibrillogenesis is only qualitative at the moment Various
morphologic species are described in the literature on
protein fibril formation Fibrillogenesis often starts with
dimers as initial building blocks [3,56] These further
oligomerize to tetramers, octamers, etc The oligomeric
species constitute prefibrillar aggregates composed of fluid
(micelle-like) nuclei [67] From these, the protofibrils grow
up to 200 nm in length and are slightly curved [67,68] All
these species accumulate in the so-called lag-phase
char-acteristic for the kinetics of fibril growth The lag-phase ends
with an exponential growth when proto-fibrils merge into
filaments Fully grown fibrils are then made from one or
more filaments added laterally or, end by end [69] The
events in the lag-phase are especially important and some
results have been obtained by real time AFM [70,71]
Presence of prefibrillar (oligomeric) intermediates is an
emerging theme [68,72]
The kinetics of fibrillogenesis have been studied by light
scattering [67,72] Teplow and coauthors [67] have
detec-ted the following steps: (a) peptide micelles form above a
certain critical concentration, (b) fibrils nucleate within
these micelles or on heterogenous nuclei (seeds), and (c)
fibrils grow by irreversible binding of monomers to the
fibril ends Simpler, colorimetric methods exist for
detect-ing amyloid fibrils Use of histological dyes Congo Red
[73] and Thioflavin T [74] is widespread In fact, both dyes
may actually label the filaments better than the fibrils
(E Zˇerovnik, unpublished observation) Thioflavin T
fluorescence is a suitable method to follow the kinetics
of fibril formation in an interrupted manner, whereas
interference with the process on longer standing would be
expected Whether Congo Red is fibril specific has been
questioned [75] Substances based on Congo Red dye
structure have been used to inhibit fibril formation in vivo
[76] and others based on Thioflavin dye structure to label
the amyloid plaques in brain imaging [77]
Teplow and coworkers [40] have recently reported that an
intermediate with additional a helixstructure was shown to
be a key step in Ab fibrillogenesis The a helical content (as
revealed by CD) was observed immediately prior to the
appearance of b structure, suggesting a precursor role for
the intermediate It was not until a helixformation had
begun that fibrils were detected by electron microscopy The
occurrence of an a helical intermediate that associates into
oligomers is not limited to Ab peptide It has also been
observed in insulin [41] and helix-turn-helix peptide [42]
The a helical intermediate is reminiscent of several cases
reported in the field of protein folding [43–46] The same
authors [40] have studied the effect of various substitutions
on the rate of a helical appearance To test the hypothesis
that aspartic acid and histidine residues control the kinetics
of a helixformation, mutations were made in Ab peptide
where Asp and His were replaced by neutral residues
Specific influence of Asp23 and His13 was observed
Substitution of His13 by Ala dramatically inhibited fibril
formation and altered fibril morphology Similarly,
substi-tution of Asp23 by Asn delayed a helixformation and fibril
formation This was explained with salt-bridges, which form
in pH range from 4 to 5.5, where Asp is negatively and His
positively charged
A mechanism for amyloid fibril formation was proposed
by Massi & Straub [78] based on the energy landscape
description The authors predict that temperature and denaturants would initially increase the rate of fibril elongation with a turnover at higher temperatures or denaturant concentrations In his study, Friedhoff [9] has shown that polyanions stimulate filament growth whereas phosphorylation retards growth
In a study based on statistical mechanics by Aggeli et al [69], the kinetics of fibril-growth of two rationally designed peptides have been compared One peptide was made more hydrophobic by replacing Glu by Phe and Trp residues At
100 lMconcentration this peptide formed b sheet ribbons and at a concentration of > 600 lM the ribbons were transformed into rigid fibrils Due to the balance of weak forces, fibril and fibre formation is characterized by slow kinetics In the particular case [69], fibril formation takes up
to several weeks to complete, as monitored by CD and TEM
Serio et al [79] have studied the yeast prion, sup 35 Detailed kinetics showed that seeding accelerated the fibril growth while, with no seeds present, a lag phase was observed During this phase, smaller fibrils (seeds) form that allow rapid assembly The lag time should decrease exponentially with increasing soluble protein concentration
if the nucleated polymerization model were applicable, which was not the case They have therefore proposed a new model, termed the nucleated conformational conversion (NCC) model, which states that oligomers lacking a conformation leading to fibril formation accumulate and associate with the nuclei where conformational conversion takes place as a rate-determining step
Several other mechanistic models, in addition to the NCC model, have been proposed: the monomer-derived conver-sion (MDC) model [60], which is similar to the template assisted (TA) model [24,60], the nucleated polymerization (NP) model proposed by Teplow and coauthors [67,72], and, lately, a mathematical model by Pallito & Murphy [80], which is termed here the off-pathway folding (OFF) model
It is difficult to judge which of the models best describes a
general process of amyloid fibril formation It may even be, similarly to protein folding, that several mechanisms apply
to different specific cases More studies of the influence of protein concentration, temperature and seeding on the rate
of amyloid fibril formation are needed A description of the two most recent models follows
Nucleated conformational conversion (NCC) model This model states that oligomers lacking a fibril-competent conformation accumulate and associate into a nucleus where conformational conversion takes place as a rate-determining step Fluid oligomeric complexes appear to be crucial intermediates in forming the amyloid nucleus When these complexes undergo a conformational change on association with the nuclei, rapid assembly follows [79] Off-pathway folding (OFF) model
In the initial refolding step, an amyloidogenic intermediate,
I, forms (A-state) in a parallel reaction [80] The step is practically irreversible, in contrast to the normal folding phase where monomer (M) and dimer (D) are in equilib-rium (equivalent to S-state) Nucleus formation follows the initial partitioning of fibril competent and noncompetent
Trang 5conformations Filament formation then takes place,
followed by filament elongation by end-to-end addition of
the intermediate I (equivalent to A-state) Fibrils form by
lateral and end-to-end association of the filaments [80] We
believe that it would be possible to include irreversible
domain-swapped dimers (A-state dimers) in the model,
inplace of monomeric I
R O L E O F D O M A I N S W A P P I N G
I N F I B R I L L O G E N E S I S
It is to be noted that several amyloidogenic proteins form
domain swapped-dimers Such is the case with prion protein
[53], human cystatin C [36,52] and human stefin A [54,82], a
type 1 cystatin It remains to be seen if these irreversible
transitions, due to high energetic barriers [81,82], have
relevance to amyloidogenesis
Eisenberg and coworkers have proposed a method by
which domain-swapped dimers could lead to higher
oligomerization and amyloid fibrillization [30,81] If the
exchange of secondary structure elements is not
recipro-cated but propagated along multiple polypeptide chains,
higher order assemblies may form In principle, any protein
is capable of oligomerization by 3D domain-swapping [83]
By designing an a helical structure that could domain swap,
Eisenberg et al [84] have shown that it was possible to
design a sequence that permits a reciprocated swap and
another that promotes a propagated swap Indeed,
domain-swapped dimer and fibrils resulted, as expected An
interesting observation was also made with ribonuclease
where pair of domain-swapped structures involving N- and
C-terminal parts can coexist This suggests another possible
mechanism for propagated domain swapping [30]
Staniforth et al [54] discuss ways in which the
domain-swapped dimer of cystatin could propagate into a fibrillar
structure It is assumed that open ends on the N- and
C-termini would allow further interactions The electronic
density of a generic fibril could be fitted by two rows of
dimers, each row extending in both directions indefinitely
(Fig 2) Janowski et al who determined the crystal
struc-ture of human cystatin C domain-swapped dimer [52],
believe that the dimers most probably represent a dead end
to further amyloidogenesis or, at least, hinder the process
If domain-swapped dimers were rate-limiting for fibril
formation, a high energetic barrier would be expected; this
could be deduced from the influence of temperature on
the process In the case of plant monnelin, a structurally
analogous protein to cystatins, the authors [85] did not
look for existence of the dimer It has been found that
heating was needed for the prenucleus stage of fibril
growth and that maturation of the nucleus proceeded at
lower temperature A similar observation has been made
with human stefin A (cystatin A), which demonstrates a
high activation energy of 99 kcalÆmol)1 for domain
swapping [82] and forms dimers when heated to 85°C
for 1 h A preheated sample can make fibrils at ambient
temperature if the structure is additionally destabilized by
lowering pH to 2.4 (E Zˇerovnik, unpublished
observa-tion) More importantly, the disease-causing variant of
human cystatin C (L68Q) forms dimers under
physiolo-gical conditions [36]
It has been suggested by Bergdoll et al [86] and
confirmed by Itzhaki and coauthors [87] that a proline in
the linker region might facilitate domain swap It could rigidify the hinge region and keep it extended [83] Parallel reactions in folding have largely been attributed to the difference in peptide bond configuration at some critical proline [88] in the denatured state ensemble This option, too, should be considered in searching for an explanation for slow formation of domain-swapped dimers and fibrils The energy of activation determined for the lag and growth phases in a-synuclein fibrillization [39] was 20 kcalÆmol)1, which would be consistent with a proline isomerization reaction Of course, there may be other slow events with high activation energy It has been found that a slow rate of unfolding (a high E barrier) prevents amyloid fibril forma-tion [89] and that fast unfolding leads to increased rate of fibrillization
C O N N E C T I O N O F P R O T E I N F I B R I L
F O R M A T I O N T O P A T H O P H Y S I O L O G Y
A N D D I S E A S E
So far, about 20 human proteins have been found in proteinaceous deposits in various conformational diseases These do not demonstrate any sequence or structural homology The common event is thought to be a conformational change, leading to lack of biological function or gain of toxic activity, and possibly, formation
of amyloid fibrils
It is a matter of debate as to whether the fibrillar aggregates and amyloid plaques are the side-product of some other pathology or whether they are the main cause of the disease Co-localization of protein aggregates with degenerating tissue and association of their presence with disease symptoms are a strong indication of the involvement
of amyloid deposition in the pathogenesis of
conformation-al diseases [20] In familiconformation-al cases of some neurodegenerative diseases (Table 1), evidence has been obtained for a direct link between the ability of mutated protein to form fibrils and the appearance of signs of the pathology [2,90] Studies with transgenic animals have also confirmed the contribu-tion of the mutacontribu-tion in the amyloidogenic protein and disease pathogenesis [20,91,92]
Whether the fibrils or the prefibrillar aggregates are the dangerous species for the cell metabolism is still disputed In animal studies it has been shown that significant tissue damage and clinical symptoms appear before any protein aggregates are detected, implicating an intermediate on the amyloidogenic pathway, which could be the real cause of the pathogenesis [3,4,6,7] It was proposed that protein aggregation into fibrils could even represent a protective event that depletes the cell of the toxic prefibrillar species [3] Careful usage of fibril inhibitors is indicated as they may cause accumulation of the toxic precursor [68]
Evidence has been obtained in studies on Alzheimer’s disease that fibrils are not the most neurotoxic form of Ab [6] The peptide also assembles into soluble proto-fibrils and smaller oligomers The proto-fibril of Ab was shown by AFM to be a slightly curved, of 4–11 nm diameter and
< 200 nm long [56] Isolated protofibrils were found to be toxic, causing oxidative stress and, eventually, neural death [72,93] The smaller oligomers can interfere with signal transduction, possibly binding a tyrosine kinase important for memory formation (long-term synaptic potentiation) and sau phosphorylation [6]
Trang 6In prion diseases [20,24,94], no abundant amyloid
deposition was found in the brain, even though PrPSc
(the disease-related conformer of the protein) has a strong
tendency to aggregate in vitro An interesting observation
was made that PrPC (the normal, cellular protein) binds
to survival factors and that the PrPCto PrPSc transition
might result in apoptotic cell death In Huntington’s
disease, activation of microglia following disruption of
neuronal architecture may be the death trigger rather
than the apoptotic pathway [91] This is consistent with
findings in a transgenic mouse model of Huntington’s
disease, where cell death was neither apoptotic nor
necrotic [92]
M E A N S O F N A T U R A L D E F E N C E A N D
R E G U L A T I O N
Cellular defence against unfolded and aberrantly folded
proteins consists of several protective systems that prevent
aggregation, refold unfolded proteins or, degrade them If
the rate of damage to cellular proteins is increased, for
example on exposure to increased temperature, oxygen free
radicals or other stress conditions, or when mutations occur,
this can disturb normal cellular functions and trigger
apoptosis [95] In such harsh conditions, cells respond by
the induction of heat shock proteins (Hsp) that comprise
chaperones, antioxidant enzymes and
ubiquitin–protea-some components The largest group of heat shock proteins
act as chaperones that bind to denatured or partially folded
proteins [96–98] Certain combinations of chaperones, in
particular Hsp70, Hsp104 and Hsp40, can serve to
dis-assemble intracellular protein aggregates [99] Especially,
Hsp104 was found to be of importance for disassembly–
disaggregation [97,100]
The ubiquitin- and proteasome-mediated degradation of
proteins plays an important role in cellular quality control
by removing mutated, misfolded and post-translationally
damaged proteins [20,100] In many cellular inclusions
ubiquinated proteins are found together with proteasome
components [100] If the cell is still overburdened by
aggregated proteins, apoptosis programs are switched on
A novel finding is that heat shock proteins have a dual
function As well as a role in refolding aberrantly folded
proteins and keeping them from aggregation, a second
function involves regulation of apoptosis [95,101] Among
the heat shock proteins are anti-apoptotic and
pro-apoptotic proteins [101] The recently discovered BAG
family of proteins operate as molecules that recruit
chaperones to target proteins Such diverse proteins as
Bcl2, Raf1, various receptor, transcription factor
mole-cules and Hsp70 compete for binding to members of the
BAG-family of proteins [102] This binding induces
changes in protein conformation that may have a
profound effect on protein function Unfortunately,
studying the conformational changes in proteins in vivo
remains rather elusive
N O V E L T H E R A P E U T I C A P P R O A C H E S
Novel therapeutic approaches are being directed towards
achieving one of the following goals: either to inhibit and/or
reverse the conformational change, or to dissolve the
smaller aggregates and disassemble the amyloid fibrils
Several successful attempts have been cited in the literature including the use of monoclonal antibodies that bind to the active conformation of the protein and thus inhibit conformational changes In Alzheimer’s disease, vacci-nation is on the horizon, in this case targeting the smaller oligomers and prefibrillar aggregates [103] Soto and coworkers have designed the so called mini-chaperones, also termed b sheet breakers [20,24], which are peptides that bind to the sequence of the protein region responsible for self association In the prion disease, similarly to Alzheimer’s, trials are underway using monoclonal anti-bodies that prevent conformational change [104] Some drugs already in use for other purposes have been screened and several were found that both retard or reverse neuro-degeneration if used for early intervention and also improve the disease state in quite desperate cases, as reported by the Prusiner’s group [105] One of these drugs, quinacrine, is an anti-malarial agent and the other, chlorpromazine, is used
to treat schizophrenia Other blockers of amyloid fibril formation have been found, ranging from Congo Red derivatives, anti-cancer and antibiotic drugs to nicotine and melatonin [76]
C O N C L U S I O N S
Understanding amyloid-fibril formation may contribute to resolving some of the today’s most devastating diseases and,
at the very least, increase our general knowledge about protein structure, folding and stability Many properties of amyloid fibrils have emerged: a common structure for filaments and fibrils [58], nucleation dependent kinetics [67], the role of oligomeric intermediates [68,72] and the existence
of at least two protein conformations separated by a high energetic barrier, which behave as two macroscopic states [64,81] The following are some of the challenges still facing us:
(a) Can domain-swapping be a mechanism for fibrilliza-tion of globular proteins?
(b) What is the role of a helical parts of proteins? Do they remain helical in the fibrils? (Periodicity characteristic for
a helices has been observed in an X-ray diffraction study on the apolipoprotein A1 variant [106])
(c) What is the role of a helical intermediates observed in folding [107] and fibrillization studies [40] where temporarily non-native a helices appear?
A C K N O W L E D G E M E N T S
For financial support the author thanks the Ministry of Education, Science and Sport of the Republic of Slovenia Professor R H Pain (JSI, Ljubljana, Slovenia) is indebted for reading the manuscript, giving useful comments and editing English I also thank T Zavasˇnik-Bergant (JSI, Ljubljana, Slovenia) and K Goldie (EMBL, Heidelberg, Germany) for taking the TEM picture reproduced in Fig 1 I am thankful to M Ravnikar and M Pompe-Novak (both National Institute of Biology, Ljubljana) and I Musˇevic and M Sˇkarabot (Department of Physics, JSI, Ljubljana) for continuous TEM and AFM work on human stefins My gratitude goes to Professor V Turk and his team: L Kroon-Zˇitko and M Kenig (at JSI, Ljubljana), for preparing the recombinant stefins The author additionally thanks J P Waltho for the model of cystatin A–stefin A dimer reproduced in Fig 2B, and to R A Staniforth (Krebs Institute, University of Sheffield, UK) for reading the manuscript and giving useful sugges-tions.
Trang 7R E F E R E N C E S
1 Raso, S.W & King, J.K (2000) Protein folding and human
disease In Mechanisms of Protein Folding (Pain R.H., ed.)
Frontiers in Molecular Biology Series, pp 406–428 Oxford
University Press, Oxford.
2 Goedert, M., Spillantini, M.G & Davies, S.W (1998)
Fila-mentous nerve cell inclusions in neurodegenerative diseases Curr.
Opin Neurobiol 8, 619–632.
3 Roher, A.E., Baudry, J., Chaney, M.O., Kuo, Y.M., Stine, W.B.
& Emmerling, M.R (2000) Oligomerizaiton and fibril asssembly
of the amyloid-b protein Biochim Biophys Acta 502, 31–43.
4 Selkoe, D.J (1994) Normal and abnormal biology of the
b-amyloid precursor protein Annu Rev Neurosci 17, 489–517.
5 Wanker, E.E (2000) Protein aggregation in Huntington’s and Parkinson’s disease: implications for therapy Mol Med Today 6, 387–391 Review.
6 Klein, W.L., Krafft, G.A & Finch, C.E (2001) Targeting small
Ab oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24, 219–224 Review.
7 Selkoe, D.J (2001) Presenilin, Notch, and the genesis and treat-ment of Alzheimer’s disease Proc Natl Acad Sci USA 98, 11039–11041.
8 Smith, M.A., Rottkamp, C.A., Nunomura, A., Raina, A.K & Perry, G (2000) Oxidative stress in Alzheimer’s disease Biochim Biophys Acta 1502, 139–144.
9 Friedhoff, P., von Bergen, M & Mandelkow, E.M (2000) Structure of sau protein and assembly into paired helical fila-mements Biochim Biophys Acta 1502, 122–132.
10 Ray, I., Chauhan, A., Wegiel, J & Chauhan, V.P (2000) Gelsolin inhibits the fibrillization of amyloid b-protein, and also defibril-lizes its preformed fibrils Brain Res 853, 344–351.
11 Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., Gerard, C., Hama, E., Lee, H.J & Saido, T.C (2001) Metabolic regulation of brain Ab by neprilysin Science 292, 1550–1552.
12 Ciechanover, A (2001) Linking ubiquitin, parkin and
synphilin-1 Nat Med 7, 1108–1109.
13 Murray, I.V.J., Lee, V.M.-Y & Trojanowski, J.Q (2001) Synu-cleinopathies: a pathological and molecular review Clin Neurosci Res 1, 455–455.
14 Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P.J & Haass, C (2000) Con-stitutive phosphorylation of the Parkinson’s disease associated a-synuclein J Biol Chem 275, 390–397.
15 Ellis, C.E., Schwartzberg, P.L., Grider, T.L., Fink, D.W & Nussbaum, R.L (2001) a-Synuclein is phosphorylated by mem-bers of the Src family of protein-tyrosine kinases J Biol Chem.
276, 3879–3884.
16 Nakamura, T., Yamashita, H., Takahashi, T & Nakamura, S (2001) Activated Fyn phosphorylates a-synuclein at tyrosine residue 125 Biochem Biophys Res Commun 280, 1085–1092.
17 Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, V.L & Dawson, T.M (2001) Parkin ubiquitinates the a-synuclein-interacting protein, synphi-lin-1: implications for Lewy-body formation in Parkinson disease Nat Med 7, 1144–1150.
18 Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R & Goedert, M (1997) a-Synuclein in Lewy bodies Nature 388, 839–840.
19 Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K & Suzuki, T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase Nat Genet 25, 302–305.
20 Soto, C (2001) Protein misfolding and disease; protein refolding and therapy FEBS Lett 498, 204–207.
21 Cohen, F.E (2000) Prions, peptides and protein misfolding Mol Med Today 6, 292–293.
22 Cohen, A.S (1986) General introduction and brief history of the amyloid fibril In Amyloidosis (Marrink, J & Van Rijswijk, M.H., eds), pp 3–19 Nijhoff, Dordrecht.
23 Sipe, J.D & Cohen, A.S (2000) History of the amyloid fibril.
J Struct Biol 130, 88–98.
24 Soto, C & Saborio, G.P (2001) Prions: disease propagation and disease therapy by conformational transmission Trends Mol Med 7, 109–114.
25 Damaschun, G., Damaschun, H., Fabian, H., Gast, K., Krober, R., Wieske, M & Zirwer, D (1999) Conversion of yeast phosphoglycerate kinase into amyloid-like structure Proteins 39, 204–211.
Fig 2 Scheme representing amyloid fibril formation from ‘cystatin’
domain-swapped dimers (A) Electron density obtained by cryo-EM,
looking inside a fibril from SH3 domain, reproduced from [57], with
permission (B) Three-dimensional model of a domain-swapped dimer,
representative of the cystatin superfamily (C) One possible mode of
how the domain-swapped dimers could build up the fibril The scheme
is adapted from [54], with permission.
Trang 826 Litvinovich, S.V., Brew, S.A., Aota, S., Akiyama, S.K.,
Hau-denschild, C & Ingham, K.C (1998) Formation of amyloid-like
fibrils by self association of a partially unfolded fibronectin type
III module J Mol Biol 280, 245–258.
27 Guijarro, J.I., Sunde, M., Jones, J.A., Campbell, I.D & Dobson,
C.M (1998) Amyloid fibril formation by an SH3 domain Proc.
Natl Acad Sci USA 95, 4224–4228.
28 Konno, T., Murata, K & Nagayama, K (1999) Amyloid-like
aggregates of a plant protein: a case of a sweet-tasting protein,
monellin FEBS Lett 454, 122–126.
29 Chiti, F., Webster, P., Taddei, N., Clark, A., Stefani, M.,
Ram-poni, G & Dobson, C.M (1999) Designing conditions for in
vitro formation of amyloid protofilaments and fibrils Proc Natl
Acad Sci USA 96, 3590–3594.
30 Liu, Y., Gotte, G., Libonati, M & Eisenberg, D (2001) A
domain-swapped RNase A dimer with implications for amyloid
formation Nat Struct Biol 8, 211–214.
31 Zˇerovnik, E., Pompe-Novak, M., Sˇkarabot, M., Ravnikar, M.,
Musˇevic, I & Turk, V (2002) Human stefin B readily forms
amyloid fibrils in vitro Biochim Biophys Acta 1594, 1–5.
32 Fa¨ndrich, M., Fletcher, M.A & Dobson, C.M (2001) Amyloid
fibrils from muscle myoglobin Nature 410, 165–166.
33 Pertinhez, T.A., Bouchard, M., Tomlinson, E.J., Wain, R.,
Ferguson, S.J., Dobson, C.M & Smith, L.J (2001) Amyloid fibril
formation by a helical cytochrome FEBS Lett 495, 184–186.
34 Dobson, C.M (1999) Protein misfolding, evolution and disease.
Trends Biochem Sci 24, 329–332.
35 Rochet, J.C & Lansbury, P.T Jr (2000) Amyloid fibrillogenesis:
themes and variations Curr Opin Struct Biol 10, 60–68.
36 Ekiel, I & Abrahamson, M (1996) Folding-related dimerization
of human cystatin C J Biol Chem 271, 1314–1321.
37 Lai, Z., Colon, W & Kelly, J.W (1996) The acid-mediated
denaturation pathway of transthyretin yields a conformational
intermediate that can self-assemble into amyloid Biochemistry
35, 6470–6482.
38 Uversky, V.N., Gillespie, J.R & Fink, A.L (2000) Why are
natively unfolded proteins unstructured under physiologic
conditions? Proteins 41, 415–427.
39 Uversky, V.N., Li, J & Fink, A.L (2001) Evidence for a partially
folded intermediate in a-synuclein fibril formation J Biol Chem.
276, 10737–10744.
40 Kirkitadze, M.D., Condron, M.M & Teplow, D.B (2001)
Identification and characterization of key kinetic intermediates in
amyloid b-protein fibrillogenesis J Mol Biol 312, 1103–1119.
41 Bouchard, M., Zurdo, J., Nettleton, E.J., Dobson, C.M &
Robinson, C.V (2000) Formation of insulin amyloid fibrils
followed by FTIR simultaneously with CD and electron
micro-scopy Protein Sci 9, 1960–1967.
42 Fezoui, Y., Hartley, D.M., Walsh, D.M., Selkoe, D.J., Osterhout,
J.J & Teplow, D.B (2000) A de novo designed helix-turn-helix
peptide forms nontoxic amyloid Nat Struct Biol 7, 1095–1099.
43 Hamada, D & Goto, Y (1997) The equilibrium intermediate of
b-lactoglobulin with non-native a-helical structure J Mol Biol.
269, 479–487.
44 Hamada, D., Segawa, S & Goto, Y (1996) Non-native a-helical
intermediate in the refolding of b-lactoglobulin, a predominantly
b-sheet protein Nat Struct Biol 3, 868–873.
45 Lu, H., Buck, M., Radford, S.E & Dobson, C.M (1997)
Acceleration of the folding of hen lysozyme by trifluoroethanol.
J Mol Biol 265, 112–117.
46 Zˇerovnik, E., Virden, R., Jerala, R., Kroon-Zˇitko, L., Turk, V &
Waltho, J.P (1999) Differences in the effects of TFE on the
folding pathways of human stefins A and B Proteins 36, 205–216.
47 Buck, M (1998) Trifluoroethanol and colleagues: cosolvents
come of age Recent studies with peptides and proteins Q Rev.
Biophys 31, 297–355.
48 Chiti, F., Taddei, N., Webster, P., Hamada, D., Fiaschi, T., Ramponi, G & Dobson, C.M (1999) Acceleration of the folding
of acylphosphatase by stabilisation of local secondary structure Nat Struct Biol 6, 380–387.
49 Liu, K., Cho, H.S., Lashuel, H.A., Kelly, J.W & Wemmer, D.E (2000) A glimpse of a possible amyloidogenic intermediate of transthyretin Nat Struct Biol 7, 754–757.
50 Hosszu, L.L., Baxter, N.J., Jackson, G.S., Power, A., Clarke, A.R., Waltho, J.P., Craven, C.J & Collinge, J (1999) Structural mobility of the human prion protein probed by backbone hydrogen exchange Nat Struct Biol 6, 740–743.
51 Nettleton, E.J., Tito, P., Sunde, M., Bouchard, M., Dobson, C.M & Robinson, C.V (2000) Characterization of the oligo-meric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry Biophys J 79, 1053–1065.
52 Janowski, R., Kozak, M., Jankowska, E., Grzonka, Z., Grubb, A., Abrahamson, M & Jaskolski, M (2001) Human cystatin C,
an amyloidogenic protein, dimerizes through three-dimensional domain swapping Nat Struct Biol 8, 316–320.
53 Knaus, K.J., Morillas, M., Swietnicki, W., Malone, M., Surewicz, W.K & Yee, V.C (2001) Crystal structure of the human prion protein reveals a mechanism for oligomerization Nat Struct Biol 8, 770–774.
54 Staniforth, R.A., Giannini, S., Higgins, L.D., Conroy, M.J., Hounslow, A.M., Jerala, R., Craven, C.J & Waltho, J.P (2001) Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural super-family EMBO J 20, 4774–4781.
55 Goldsbury, C.S., Cooper, G.J., Goldie, K.N., Muller, S.A., Saafi, E.L., Gruijters, W.T., Misur, M.P., Engel, A., Aebi, U & Kistler,
J (1997) Polymorphic fibrillar assembly of human amylin.
J Struct Biol 119, 17–27.
56 Ding, T.T & Harper, J.D (1999) Analysis of amyloid-b assem-blies using tapping mode atomic force microscopy under ambient conditions Methods Enzymol 309, 510–525.
57 Jimenez, J.L., Guijarro, J.I., Orlova, E., Zurdo, J., Dobson, C.M., Sunde, M & Saibil, H.R (1999) Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing EMBO J 18, 815–821.
58 Serpell, L.C (2000) Alzheimer’s amyloid fibrils: structure and assembly Biochim Biophys Acta 1502, 16–30.
59 Tycko, R (2001) Solid-state nuclear magnetic resonance tech-niques for structural studies of amyloid fibrils Methods Enzymol.
339, 390–413.
60 Kelly, J.W (2000) Mechanisms of amyloidogenesis Nat Struct Biol 7, 824–826.
61 Lansbury, P.T Jr (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease Proc Natl Acad Sci USA 96, 3342–3344.
62 Kad, N.M & Radford, S.E (2001) Partial unfolding as a pre-cursor to amyloidosis: a discussion of the occurrence, role, and implications In Molecular Chaperones in the Cell (Lund, P., ed.), Frontiers in Molecular Biology Series, pp 257–278 Oxford University Press, Oxford.
63 Carrel, R.W & Gooptu, B (1998) Conformational changes and disease – serpins, prions and Alzheimer’s Curr Opin Struct Biol.
8, 799–809.
64 Ferreira, S.T & De Felice, F.G (2001) PABMB Lecture Protein dynamics, folding and misfolding: from basic physical chemistry
to human conformational diseases FEBS Lett 498, 129–134.
65 Damaschun, G., Damaschun, H., Gast, K & Zirwer, D (1999) Proteins can adopt totally different folded conformations J Mol Biol 291, 715–725.
66 Kelly, J.W (1998) The alternative conformations of amyloido-genic proteins and their multi-step assembly pathways Curr Opin Struct Biol 8, 101–106.
Trang 967 Lomakin, A., Chung, D.S., Benedek, G.B., Kirschner, D.A &
Teplow, D.B (1996) On the nucleation and growth of amyloid
b-protein fibrils detection of nuclei and quantitation of rate
constants Proc Natl Acad Sci USA 93, 1125–1129.
68 Harper, J.D., Wong, S.S., Lieber, C.M & Lansbury, P.T Jr
(1999) Assembly of A b amyloid protofibrils: an in vitro model for
a possible early event in Alzheimer’s disease Biochemistry 38,
8972–8980.
69 Aggeli, A., Nyrkova, I.A., Bell, M., Harding, R., Carrick, L.,
McLeish, T.C., Semenov, A.N & Boden, N (2001) Hierarchical
self-assembly of chiral rod-like molecules as a model for peptide
b-sheet tapes, ribbons, fibrils, and fibers Proc Natl Acad Sci.
USA 98, 11857–11862.
70 Goldsbury, C., Kistler, J., Aebi, U., Arvinte, T & Cooper, G.J.
(1999) Watching amyloid fibrils grow by time-lapse atomic force
microscopy J Mol Biol 285, 33–39.
71 Blackley, H.K., Sanders, G.H., Davies, M.C., Roberts, C.J.,
Tendler, S.J & Wilkinson, M.J (2000) In-situ atomic force
microscopy study of b-amyloid fibrillization J Mol Biol 298,
833–840.
72 Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y.,
Con-dron, M.M., Lomakin, A., Benedek, G.B., Selkoe, D.J &
Teplow, D.B (1999) Amyloid b-protein fibrillogenesis Structure
and biological activity of protofibrillar intermediates J Biol.
Chem 274, 25945–25952.
73 Klunk, W.E., Jacob, R.F & Mason, R.P (1999) Quantifying
amyloid by congo red spectral shift assay Methods Enzymol 309,
285–305.
74 Le Vine, H (1999) Quantification of b sheet amyloid fibril
structures with thioflavin T Methods Enzymol 309, 274–284.
75 Khurana, R., Uversky, V.N., Nielsen, L & Fink, A.L (2001) Is
Congo red an amyloid-specific dye? J Biol Chem 276, 22715–
22721.
76 Findeis, M.A (2000) Approaches to discovery and
characteri-zation of inhibitors of amyloid b-peptide polymericharacteri-zation.
Biochim Biophys Acta 1502, 76–84 Review.
77 Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt,
D.P & Mathis, C.A (2001) Uncharged thioflavin-T derivatives
bind to amyloid-b protein with high affinity and readily enter the
brain Life Sci 69, 1471–1484.
78 Massi, F & Straub, J.E (2001) Energy landscape theory for
Alzheimer’s amyloid-peptide fibril elongation Proteins 42,
217–229.
79 Serio, T.R & Lindquist, S.L (2000) Nucleated conformational
conversion and the replication of conformational information by
a prion determinant Science 289, 1317–1321.
80 Pallitto, M.M & Murphy, R.M (2001) A mathematical model of
the kinetics of b-amyloid fibril growth from the denatured state.
Biophys J 81, 1805–1822.
81 Schlunegger, M.P., Bennett, M.J & Eisenberg, D (1997)
Oligo-mer formation by 3D domain swapping: a model for protein
assembly and misassembly Adv Protein Chem 50, 61–122.
82 Jerala, R & Zˇerovnik, E (1999) Accessing the global minimum
conformation of stefin A dimer by annealing under partially
denaturing conditions J Mol Biol 291, 1079–1089.
83 Newcomer, M.E (2002) Protein folding and three-dimensional
domain swapping: a strained relationship? Curr Opin Struct.
Biol 12, 48–53.
84 Ogihara, N.L, Ghirlanda, G., Bryson, J.W., Gingery, M.,
DeG-rado, W.F & Eisenberg, D (2001) Design of three-dimensional
domain-swapped dimers and fibrous oligomers Proc Natl Acad.
Sci USA 98, 1404–1409.
85 Konno, T (2001) Multistep nucleus formation and a separate
subunit contribution of the amyloidgenesis of heat-denatured
monellin Protein Sci 10, 2093–2101.
86 Bergdoll, M., Remy, M.H., Cagnon, C., Masson, J.M & Dumas,
P (1997) Proline-dependent oligomerization with arm exchange Structure 5, 391–401.
87 Rousseau, F., Schymkowitz, J.W., Wilkinson, H.R & Itzhaki, L.S (2001) Three-dimensional domain swapping in p13suc1 oc-curs in the unfolded state and is controlled by conserved proline residues Proc Natl Acad Sci USA 98, 5596–5601.
88 Balbach, J & Schmid, F.X (2000) Proline isomerization and its catalysis in protein folding In Mechanisms of Protein Folding (Pain, R.H ed.) Frontiers in Molecular Biology Series, pp 213–249 Oxford University Press, Oxford.
89 Plaza del Pino, I.M., Ibarra-Molero, B & Sanchez-Ruiz, J.M (2000) Lower kinetic limit to protein thermal stability: a proposal regarding protein stability in vivo and its relation with misfolding diseases Proteins 40, 58–70.
90 Conway, K.A., Harper, J.D & Lansbury, P.T (1998) Accelerated in vitro fibril formation by a mutant a-synuclein linked to early-onset Parkinson disease Nat Med 4, 1318–1320.
91 Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G.P., Davies, S.W., Lehrach, H & Wanker, E.E (1997) Huntingtin-encoded poly-glutamine expansions form amyloid-like protein aggregates
in vitro and in vivo Cell 90, 549–558.
92 Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G.P.
& Davies, S.W (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington’s disease Proc Natl Acad Sci USA 97, 8093–8097.
93 Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B & Selkoe, D.J (1999) Protofibrillar intermediates of amyloid b-protein induce acute electrophysio-logical changes and progressive neurotoxicity in cortical neurons.
J Neurosci 19, 8876–8884.
94 Nicotera, P.A (2001) Route for prion neuroinvasion Neuron 31, 345–348.
95 Sherman, M.Y & Goldberg, A.L (2000) Cellular defenses against unfolded proteins: a cell biologist thinks about neurode-generative diseases Neuron 29, 15–32.
96 Badcoe, I.G., Smith, C.J., Wood, S., Halsall, D.J., Holbrook, J.J., Lund, P & Clarke, A.R (1991) Binding of a chaperonin to the folding intermediates of lactate dehydrogenase Biochemistry 30, 9195–9200.
97 Leroux, M.R & Hartl, F.U (2000) Cellular functions of mole-cular chaperones In Mechanisms of Protein Folding (Pain R.H., ed.) Frontiers in Molecular Biology Series, pp 364–405 Oxford University Press, Oxford.
98 Mogk, A., Bukau, B & Deuerling, E (2001) Cellular functions of cytosolic E.coli chaperones In Molecular Chaperones in the Cell (Lund, P., ed.) Frontiers in Molecular Biology Series, pp 1–34 Oxford University Press, Oxford.
99 Glover, J.R & Lindquist, S (1998) Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins Cell 94, 73–82.
100 Alves-Rodrigues, A., Gregori, L & Figueiredo-Pereira, M.E (1998) Ubiquitin, cellular inclusions and their role in neurode-generation Trends Neurosci 21, 516–552.
101 Garrido, C., Gurbuxani, S., Ravagnan, L & Kroemer, G (2001) Heat shock proteins: endogenous modulators of apoptotic cell death Biochem Biophys Res Commun 286, 433–442.
102 Takayama, S & Reed, J.C (2001) Molecular chaperone targeting and regulation by BAG family proteins Nat Cell Biol 3, E237– E241.
103 Ingram, D.K (2001) Vaccine development for Alzheimer’s disease: a shot of good news Trends Neurosci 24, 305–307.
104 Jones, R (2001) Blocking prion conversion Highlights Nat Rev Neurosci 2, 605.
Trang 10105 Korth, C., May, B.C., Cohen, F.E & Prusiner, S.B (2001)
Acridine and phenothiazine derivatives as pharmacotherapeutics
for prion disease Proc Natl Acad Sci USA 98, 9836–9841.
106 Mangione, P., Sunde, M., Giorgetti, S., Stoppini, M., Esposito,
G., Gianelli, L., Obici, L., Asti, L., Andreola, A., Viglino, P.,
Merlini, G & Bellotti, V (2001) Amyloid fibrils derived from the
apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure Protein Sci 10, 187–199.
107 Hamada, D., Chiti, F., Guijarro, J.I., Kataoka, M., Taddei, N & Dobson, C.M (2000) Evidence concerning rate-limiting steps in protein folding from the effects of trifluoroethanol Nat Struct Biol 7, 58–61.